GlassScriptPhysician profile
Julio C Ayala
NPI 1104883347
$2,157.43
in general payments reported to CMS, 2019-2025
16 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $241 · 2022: $108 · 2023: $797 · 2024: $541 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.05 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.00 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $252.29 | 2019-2024 | Simponi, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $246.17 | 2019-2025 | Entyvio, Gattex |
| Celgene Corporation | $163.17 | 2022-2023 | Zeposia |
| Covidien LP | $124.92 | 2020 | |
| Qol Medical, LLC | $96.40 | 2023 | Sucraid |
| Genzyme Corporation | $95.76 | 2023 | |
| Organon LLC | $75.72 | 2023-2024 | Renflexis, Hadlima |
| Ironwood Pharmaceuticals, INC | $42.99 | 2022-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $35.36 | 2024 | Voquezna |
| Ardelyx, INC. | $19.19 | 2024 | Ibsrela |
| Braintree Laboratories, INC. | $18.39 | 2020 | |
| Alfasigma USA, INC. | $14.75 | 2020 | |
| Gilead Sciences, INC. | $12.50 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Ayala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.